Alto Neuroscience (ANRO) vs Cullinan Therapeutics (CGEM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alto Neuroscience (ANRO) has outperformed Cullinan Therapeutics (CGEM) over the past year, gaining 296.0% versus a gain of 165.4%. Cullinan Therapeutics is the larger company by market cap ($960.6 million vs $923.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANRO | CGEM |
|---|---|---|
| Share price | $23.52 | $15.63 |
| Market cap | $922.97M | $960.59M |
| 1-day change | -0.72% | -3.82% |
| YTD return | +32.13% | +51.01% |
| 1-year return | +295.96% | +165.37% |
| 5-year return | — | -37.48% |
| EPS (TTM) | $-2.31 | $-3.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.48 | $23.19 |
| 52-week low | $5.23 | $5.85 |
| Distance from 52-week high | -37.25% | -32.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.18% | +114.01% |
| Average volume | 543.14K | 868.12K |
| Shares outstanding | 39.24M | 61.46M |
| Employees | 68 | 109 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANRO has outperformed CGEM by 130.6 percentage points over the past year.
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Healthcare · Biotechnology · 68 employees
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Healthcare · Biotechnology · 109 employees
ANRO vs CGEM FAQ
Which is bigger, Alto Neuroscience or Cullinan Therapeutics?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $960.59M compared with $922.97M for Alto Neuroscience (ANRO).
Which stock has performed better over the past year, ANRO or CGEM?
ANRO returned +295.96% over the past 12 months, compared with +165.37% for CGEM (price return, excluding dividends). Past performance does not predict future results.
Are Alto Neuroscience and Cullinan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.